Abiopharma

🔍 O'Connell Katrina (Executive)

Company: GAP INC (GAP)

Report Date: 2026-03-16

Detailed Transactions and Holdings:

• Acquired 225,000 shares of Common Stock (Direct)
  Date: 2026-03-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 232,718.00 | transaction_form_type: 4
• Sold 113,563 shares of Common Stock at $23.24 per share (Direct)
  Date: 2026-03-16 | Code: F | equity_swap_involved: 0 | shares_owned_after: 119,155.00 | transaction_form_type: 4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-16 | Code: H | nature_of_ownership: by Trust | shares_owned_after: 670.29 | Footnotes: F1
• Acquired 89,534 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 236,611.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: The reporting person and members of her immediate family are among the beneficiaries of this family trust. The reporting person disclaims beneficial ownership of the Gap Inc. common stock held by the trust except to the extent of her pecuniary interest therein.
• F2: Each restricted stock unit represents a contingent right to receive one share of Gap Inc. Common Stock.
• F3: On March 16, 2026, the reporting person was granted 89,534 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.